ArticleCardiology and therapy2015

Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden.

Najida Begum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.